CYDY — CytoDyn Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1175680 ·
Last close
$0.21
Market Cap
$290.76M
52W High
$0.40
52W Low
$0.18
ADV30
1,398,204
Next earnings
2026-10-08
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| May 2026 | 0 | — | -6,796,000 | -9,862,000 | 13,973,000 | 11,852,000 | 123,691,000 |
| Feb 2026 | 0 | — | -6,303,000 | -4,690,000 | 18,497,000 | 15,655,000 | 122,784,000 |
| Nov 2025 | 0 | — | -5,101,000 | -22,607,000 | 8,935,000 | 4,982,000 | 128,683,000 |
| May 2025 | 0 | — | -5,066,000 | -5,956,000 | 18,047,000 | 11,903,000 | 114,089,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,465,000
Investing CF
$0
Financing CF
$18,488,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.02
As of
2026-09-06
Balance + Analyst (yfinance extras)
Retained Earnings
$-930,485,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-40,288,000
Pretax Income TTM
$-43,115,000
Interest Exp TTM
$2,827,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| May 2026 | 0 | -23,470,000 | -42,699,000 | 13,973,000 | 123,691,000 | -109,718,000 | -17,252,000 |
| May 2025 | 0 | 9,661,000 | 3,745,000 | 18,047,000 | 114,089,000 | -96,042,000 | -8,765,000 |
| May 2024 | 0 | -18,058,000 | -49,841,000 | 11,136,000 | 127,894,000 | -116,758,000 | -10,982,000 |
| May 2023 | 0 | -40,576,000 | -79,824,000 | 11,292,000 | 120,793,000 | -109,501,000 | -25,110,000 |
| May 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.18
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| UPB | Upstream Bio, Inc. | $290.29M | $5.30 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $286.51M | $2.61 | — |
| LAB | STANDARD BIOTOOLS INC. | $285.52M | $0.73 | — |
| CATX | Perspective Therapeutics, Inc. | $285.38M | $2.50 | — |
| FULC | Fulcrum Therapeutics, Inc. | $283.83M | $3.72 | — |
News headlines (Yahoo Finance, 1h cache)
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer
2026-09-19 06:02 · Yahoo
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
2026-09-01 12:30 · Yahoo
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
2026-06-11 12:30 · Yahoo
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
2026-06-04 12:00 · Yahoo
CytoDyn to Present at the LD Micro Invitational XVI
2026-05-15 12:30 · Yahoo
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
2026-04-27 12:30 · Yahoo
CytoDyn to Present at the AACR Annual Meeting 2026
2026-04-14 12:30 · Yahoo
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
2026-04-21 20:10 · Yahoo
CytoDyn to Host Investor Webcast
2026-04-23 12:30 · Yahoo
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
2026-04-22 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.